What Science Doesn't Know Yet

Most pages about ibogaine tell you what is known. This one is the other half, and on this subject it is the larger half.

Whether it works

No randomised controlled trial has demonstrated that ibogaine or noribogaine effectively treats opioid use disorder. That is the conclusion of the most recent independent review of thirty years of research.

For every other indication it is sold for, the position is worse. No randomised trial exists for PTSD, traumatic brain injury, depression, anxiety, alcohol dependence, Parkinson’s disease or multiple sclerosis. Not one person has been randomised for any of them, anywhere.

Only three randomised trials exist in the entire human literature: one in cocaine dependence, and two testing the metabolite rather than the drug.

And two randomised, blinded trials completed in 2024. Neither has posted results or published. A third completed and published in 2026, having been registered as randomised with a placebo arm and delivered as a single-arm open-label study. What the trials found sets that out.

How it works

Several mechanisms are proposed and none has been confirmed in a person.

The candidates are a nicotinic receptor, a sigma receptor, NMDA, serotonin transport and a growth factor. How ibogaine works takes each in turn.

The asymmetry is the honest summary of this compound: the one mechanism that is worked out in detail explains the harm, not the benefit. We know precisely how it can stop a heart and we do not know how it is supposed to help.

What has never been measured in a person

Each of these is a searched absence rather than an assumption.

Pharmacokinetics in liver impairment. A single liver enzyme performs almost all the clearance, and clearance across the range of that enzyme’s activity spans more than tenfold by the authors’ own figure. Nobody has studied what a damaged liver does to that. The inference is obvious and entirely untested.

Cerebellar imaging. Ibogaine kills cerebellar cells in rats, and every human who takes it loses coordination. There is no human structural imaging or volumetry of the cerebellum after ibogaine anywhere in the literature.

Sleep. Animal work shows suppression of REM sleep outlasting the drug’s other effects. No polysomnography study in humans exists.

Pregnancy and breastfeeding. Nothing. No human data, no animal reproductive toxicity study. Every protocol excludes pregnancy and none cites anything.

Echocardiography. No published ibogaine protocol used it. A provider offering one is going beyond every study ever published.

A washout period. No published source establishes one, for any drug, despite every protocol requiring people to stop things. Two of the relevant inhibitors act irreversibly or through long-lived metabolites, so the question is not academic.

Serotonin syndrome. The concern appears in every guidance document. There is no published case of it occurring with ibogaine. The pharmacological basis is real and the clinical event is undocumented, and we report both.

What has never been counted

Outcomes. No provider publishes verified outcomes and no study compares providers. Why there is no success rate sets out what one would require.

The people who relapse. The largest follow-up found seventy per cent did. They are counted once and then disappear from the literature entirely. Nobody has studied what happens to them.

Deaths, systematically. Three successive counts exist, from three different kinds of exercise with different inclusion rules, and they cannot be read as a time series. The one real denominator is two deaths among 705 people across the entire published clinical literature, which is a selected, screened, supervised population.

A dose. No regulator has approved one. A phase 1 dose-finding study was initiated in the 1990s under an approved protocol and its results were never published. A toxicological derivation from animal data yields a figure roughly two orders of magnitude below what is administered, and it has never been tested.

What has never been measured about the plant

A population. No peer-reviewed population, inventory or harvest study exists for the species. The conservation assessment’s count of mature individuals is blank.

Alkaloid variability. Published ibogaine contents range from under two per cent to over seven, across different tissues, methods and suppliers. No controlled comparison using botanically verified material has ever been published. Iboga root bark covers what follows.

What the reviews themselves ask for

Two recent systematic reviews name their own gaps, which is the most useful signal available.

One states that microdosing and escalating protocols remain experimental and lack standardised definitions, supported only by preliminary observational data, and concludes that clinical use cannot be recommended without larger controlled trials.

The other, reviewing adverse events, concludes that further research should perform clinical profiling of vulnerable populations and design effective screening methods and clinical procedures.

Read that second one carefully. In 2022 a systematic review was still calling for screening methods to be designed. The exclusion criteria every clinic applies are not the product of that work, because that work has not been done. Who should never take ibogaine traces where they came from instead.

Why this page matters more than it looks

A reader deciding about this treatment is usually choosing between a described benefit and a described risk. The described benefit rests on the absences above. The described risk does not: the cardiac mechanism is measured, replicated and counted in bodies.

That asymmetry is the single most important thing on this site, and it is why ibogaine and the heart is the page we point people to first.